Drugs / 90Y-DOTA-Epratuzumab
last change Jan 2017 re-read 2 minutes ago

90Y-DOTA-Epratuzumab

Developed for
B-cell acute lymphoblastic leukemia
Investigated by
Gilead Sciences · Institut Cancerologie de l'Ouest · Nantes University Hospital

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02577094 ? → Jan 2017 B-cell acute lymphoblastic leukemia Nantes University Hospital Withdrawn No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 90Y-DOTA-Epratuzumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT02577094